Evidence map›Paper›PMID 37861896›Full record

ArticleBulletin of experimental biology and medicine2023

Angiogenin as a Possible Mediator of Macrophage-Mediated Regulation of Fibroblast Functions.

A A Maksimova, E Ya Shevela, M A Tikhonova, T V Tyrinova, S S Bogachev, A A Ostanin, E R Chernykh

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

A A MaksimovaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia. parkinson.dses@gmail.com.
E Ya ShevelaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
M A TikhonovaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
T V TyrinovaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
S S BogachevFederal Research Center Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.
A A OstaninResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
E R ChernykhResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
Research Institute of Fundamental and Clinical Immunology · RUInstitute of Cytology and Genetics · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied angiogenin production by human macrophages and evaluated the role of this factor in the macrophage-mediated regulation of fibroblasts. All macrophage subtypes, and especially the efferocytosis-polarized macrophages, M2(LS), actively produced angiogenin. Exogenous recombinant angiogenin dose-dependently enhanced the proliferation and differentiation of dermal fibroblasts. The addition of the angiogenin inhibitor to fibroblasts cultures suppressed the stimulating effect of exogenous angiogenin or M2(LS) conditioned media. These findings indicate the involvement of angiogenin in the macrophage-mediated paracrine regulation of skin fibroblasts.

Indexed as

FibroblastsMacrophagesRibonuclease, PancreaticCulture Media, ConditionedHumansSkinangiogeninCulture Media, ConditionedRibonuclease, Pancreaticangiogeninfibroblastsmacrophagesrepair

Identifiers

PMID37861896
OpenAlexW4387798753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.